Search Results

1

Clinical and economic burden of neovascular age-related macular degeneration by disease status: A US claims-based analysis

by Almony, A., Campbell, J.H, Chen, C.-C, Keyloun, K.R, McGuiness, C.B, Multani, J.K, Shah-Manek, B.
Published 2021

Call Number: Loading...
Located: Loading...

View Fulltext in Publisher

Article
2

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: A cost-effectiveness analysis

by Agashivala, N., Carlton, R., Hassan, T., Wykoff, C.C, Yu, J.S
Published 2021

Call Number: Loading...
Located: Loading...

View Fulltext in Publisher

Article
3

Long-Term Efficacy of a Treat-and-Extend Regimen with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: An Open-Label 12-Month Extension to the CANTREAT Study

by Baker, J., CANTREAT Investigators, Galic, I.J, Greve, M., Kertes, P.J, Sheidow, T., Williams, G.
Published 2022

Call Number: Loading...
Located: Loading...

View Fulltext in Publisher

Article
4

Use of a Neural Net to Model the Impact of Optical Coherence Tomography Abnormalities on Vision in Age-related Macular Degeneration

by Ahmad, N.A, Ali, Z.C, Aslam, T.M, Balaskas, K., Mahmood, S., Thorell, M.R, Zaki, H.R
Published 2018

Call Number: Loading...
Located: Loading...

View Fulltext in Publisher
View in Scopus

Article
5

Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study

by Emerson, G.G, Koozekanani, D.D, Montezuma, S.R, Mundae, R., Naravane, A.V, Nazari, H., Santilli, C., van Kuijk, F.J.G.M, Yamanuha, J., Zhou, Y.
Published 2021

Call Number: Loading...
Located: Loading...

View Fulltext in Publisher

Article